BioDelivery Sciences International, Inc. (Nasdaq: BDSI) today announced its participation in the following upcoming investor conferences:

• Dr. Mark A. Sirgo, President and Chief Executive Officer of BioDelivery Sciences, will present at the Robert W. Baird 2009 Health Care Conference on Wednesday, September 9, 2009 at 2:45 p.m. Eastern Time in New York City.
• Dr. Sirgo will also present at the Rodman & Renshaw Annual Global Investment Conference on Thursday, September 10, 2009 at 2:00 p.m. Eastern Time in New York City.
• Dr. Andrew L. Finn, BDSI’s Executive Vice President of Product Development, will present at the NewsMakers in the Biotech Industry Conference on Wednesday, September 16, 2009 at 11:00 a.m. Eastern Time in New York City.

Dr. Sirgo and Dr. Finn will be discussing the recent FDA approval and market opportunity for ONSOLIS (fentanyl buccal soluble film) and the status of BDSI’s product pipeline, including BEMA Buprenorphine and Bioral Amphotericin B.

Live and archived webcasts of the Company’s presentations at the Robert W. Baird and Rodman & Renshaw conferences will be available at www.biodeliverysciences.com.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) is a specialty pharmaceutical company that is focused on developing innovative products to address growing market opportunities, including conditions such as pain. The company utilizes its owned and licensed patented drug delivery technologies to develop, partner, and commercialize new products using proven therapeutics. BDSI’s pain franchise currently consists of two products utilizing the Company’s patented BEMA buccal soluble film technology: ONSOLIS (fentanyl buccal soluble film) which was approved by FDA on July 16, 2009, for the management of breakthrough pain in patients with cancer, eighteen years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain, and BEMA Buprenorphine, an analgesic in Phase 2 clinical development with at least one potential target indication for the treatment of moderate to severe pain. The company is working with its BEMA technology and its patented Bioral cochleate technology on products targeted at conditions common to oncology and surgical patients such as pain and infections. The company’s headquarters is located in Raleigh, North Carolina. For more information please visit www.biodeliverysciences.com.

BDSI^®, BEMA^® and Bioral^® are registered trademarks, and ONSOLIS^TM is a trademark of BioDelivery Sciences International, Inc.

Cautionary Note on Forward-Looking Statements

This press release and the statements of representatives and partners of BioDelivery Sciences International, Inc. (the “Company”) related thereto contain, or may contain, among other things, certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” or similar expressions. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control).